论文部分内容阅读
目的：观察经导管肝动脉化疗栓塞（TACE）联合细胞因子活化杀伤（CIK）细胞治疗对原发性肝癌患者生存的影响。方法选择商丘市第一人民医院2009年8月至2013年5月期间收治的晚期原发性肝癌患者60例，均分为 TACE 联合 CIK 细胞组和 TACE 组。TACE 联合组30例采用 TACE 联合 CIK 细胞治疗；TACE 组30例，单纯采用 TACE 治疗。观察两组患者的疗效及患者的生存时间。结果 TACE 联合组有效率为33.3％，TACE 组为13.3％，两组差异有统计学意义（P<0.05）。TACE 组的中位生存期为10.0个月，1年生存率36.7%；TACE 联合组的中位生存期为15.8个月，1年生存率60.0%，均优于 TACE 组，差异有统计学意义（P<0.05）。结论TACE 联合 CIK 细胞治疗可显著提高肝癌患者的疗效，延长生存时间。“,”Objective To observe the effects of TACE combined with CIK cells on the survival of primary hepatic carcinoma patients. Methods From August 2009 to May 2013,60 cases of primary hepatic carcinoma patients were were divided into observation group and control group equally.The observation group received TACE combined with CIK,the control group received TACE only.The curative effects,survival time and 1-year survival rates were observed. Results The total RR of the observation group was 33.3%, which was significantly higher than that of the control group(13.3%).Moreover,the 1-year survival rate of the observation group was 60.0%, which was significantly higher than that of the control group(36.7%).The significant differences in RR and OS were observed between the two groups(P<0.05). Conclusion TACE combined with CIK cells could improve the curative effect,prolong the survival time of primary hepatic carcinoma patients.